BACKGROUND: Leptomeningeal metastasis (LM) is one of the major problems in the management of metastatic breast cancer; typically, LM has a devastating prognosis and often represents a terminal event. The present study analyzed the clinical features and outcome of LM in patients with breast cancer. METHODS: The medical records of patients diagnosed with LM from breast cancer at Asan Medical Center, between 2002 and 2012, were reviewed retrospectively. RESULTS: Of 95 LM patients, 38 (40 %) had an ECOG performance status (PS) ≤ 2, and the median age was 47 years (range 26-72 years). At the time of LM diagnosis, 46 patients (48.4 %) presented with coincidental failure of systemic disease control. Seventy-eight patients (82.1 %) underwent intrathecal (IT) chemotherapy, resulting in cytologic negative conversion in 26 patients, and 46 patients (48.4 %) received systemic chemotherapy. The median overall survival (OS) time was 3.3 months, and 7.8 % of the patients survived for more than 1 year. OS tended to be higher in patients who achieved cytologic negative conversion from IT chemotherapy than in those who did not (4.5 vs. 2.4 months, P = 0.088). Multivariate analysis demonstrated that ECOG PS ≤ 2, controlled extracranial disease at the time of LM diagnosis, and systemic chemotherapy after LM diagnosis were independent factors associated with survival. CONCLUSIONS: The prognosis of patients with LM from breast cancer is poor. Systemic chemotherapy, in addition to intrathecal chemotherapy, might confer a survival benefit, even after the detection of LM.
BACKGROUND:Leptomeningeal metastasis (LM) is one of the major problems in the management of metastatic breast cancer; typically, LM has a devastating prognosis and often represents a terminal event. The present study analyzed the clinical features and outcome of LM in patients with breast cancer. METHODS: The medical records of patients diagnosed with LM from breast cancer at Asan Medical Center, between 2002 and 2012, were reviewed retrospectively. RESULTS: Of 95 LM patients, 38 (40 %) had an ECOG performance status (PS) ≤ 2, and the median age was 47 years (range 26-72 years). At the time of LM diagnosis, 46 patients (48.4 %) presented with coincidental failure of systemic disease control. Seventy-eight patients (82.1 %) underwent intrathecal (IT) chemotherapy, resulting in cytologic negative conversion in 26 patients, and 46 patients (48.4 %) received systemic chemotherapy. The median overall survival (OS) time was 3.3 months, and 7.8 % of the patients survived for more than 1 year. OS tended to be higher in patients who achieved cytologic negative conversion from IT chemotherapy than in those who did not (4.5 vs. 2.4 months, P = 0.088). Multivariate analysis demonstrated that ECOG PS ≤ 2, controlled extracranial disease at the time of LM diagnosis, and systemic chemotherapy after LM diagnosis were independent factors associated with survival. CONCLUSIONS: The prognosis of patients with LM from breast cancer is poor. Systemic chemotherapy, in addition to intrathecal chemotherapy, might confer a survival benefit, even after the detection of LM.
Authors: Anna Niwińska; Katarzyna Pogoda; Wojciech Michalski; Michał Kunkiel; Agnieszka Jagiełło-Gruszfeld Journal: J Neurooncol Date: 2018-02-12 Impact factor: 4.130
Authors: Kurt A Jaeckle; Jesse G Dixon; Stephen Keith Anderson; Alvaro Moreno-Aspitia; Gerardo Colon-Otero; Kathy Hebenstreit; Tejal A Patel; Samarth L Reddy; Edith A Perez Journal: Cancer Med Date: 2020-09-03 Impact factor: 4.452
Authors: Khairul I Ansari; Arunoday Bhan; Mika Saotome; Antariksh Tyagi; Bony De Kumar; Clara Chen; Motoki Takaku; Rahul Jandial Journal: Cancer Res Date: 2021-07-09 Impact factor: 12.701
Authors: Sanziana Ri Schiopu; Gregor Habl; Matthias Haefner; Sonja Katayama; Klaus Herfarth; Juergen Debus; Florian Sterzing Journal: Cancer Manag Res Date: 2018-12-31 Impact factor: 3.989